Hester Biosciences Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2026 • Poultry Vaccines: 70.6% • Large Animal Health Products: 29.4%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Latest quarter profit grew 87.6% YoY, showing strong momentum
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.42x)
- Company has a consistent dividend-paying track record
- Company comfortably covers its interest (10.7x coverage)
- Company generates healthy free cash flow
- Company maintains a comfortable, low leverage position
CONS
- Company has delivered a poor profit growth of 5.5% over past five years
- Company has delivered a poor sales growth of 7.0% over past five years
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1933.00 | 38.34 | 463791.45 | 0.83 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9232.00 | 83.79 | 245080.59 | 0.33 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 5004.40 | 87.28 | 190351.29 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1151.20 | 25.44 | 114832.64 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1413.15 | 33.87 | 114162.52 | 0.92 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1863.00 | 92.06 | 100660.17 | 0.11 | 3620.70 | 2139.42 | 20263.10 | 1191.00 | 18.20 | 31.50 |
| LUPIN | 2152.60 | 17.80 | 98431.05 | 0.84 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2380.00 | 48.13 | 98304.73 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| DRREDDY | 1161.00 | 30.07 | 96906.34 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1656.30 | 25.67 | 95299.84 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2451.70 | 38.49 | 69193.02 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| HESTERBIO | 2182.15 | 13.63 | 1856.33 | 0.50 | 96.73 | 459.27 | 77.24 | -8.16 | 16.21 | 32.12 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 80 | 66 | 66 | 73 | 73 | 74 | 63 | 77 | 63 | 65 | 70 | 94 | 73 | |
| 69 | 54 | 54 | 60 | 60 | 59 | 54 | 63 | 51 | 53 | 54 | 62 | 55 | |
| Operating Profit | 11 | 12 | 12 | 12 | 14 | 15 | 9 | 14 | 12 | 12 | 17 | 45 | 24 |
| OPM % | 14.14% | 18.06% | 17.66% | 17.04% | 18.37% | 20.03% | 14.36% | 17.87% | 19.55% | 18.38% | 23.75% | 48.51% | 33.51% |
| Other Income | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 2 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 1 |
| Depreciation | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 5 |
| 9 | 9 | 9 | 10 | 11 | 12 | 6 | 11 | 10 | 10 | 15 | 35 | 20 | |
| Tax % | 25.89% | 25.98% | 24.85% | 27.27% | 25.38% | 25.24% | 31.59% | 16.11% | 23.81% | 27.02% | 27.12% | 24.35% | 25.52% |
| Net Profit | 6 | 7 | 6 | 7 | 8 | 9 | 4 | 10 | 8 | 7 | 11 | 26 | 15 |
| 8 | 8 | 8 | 9 | 10 | 11 | 5 | 11 | 9 | 8 | 13 | 31 | 2 | |
| Equity Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 123 | 135 | 171 | 169 | 208 | 219 | 254 | 285 | 286 | 292 | 301 | |
| 82 | 85 | 103 | 117 | 136 | 159 | 199 | 238 | 236 | 224 | 223 | |
| Operating Profit | 42 | 51 | 71 | 56 | 74 | 65 | 60 | 52 | 56 | 80 | — |
| OPM % | 34 | 38 | 41 | 33 | 35 | 30 | 24 | 18 | 19 | 27 | — |
| Other Income | 1 | 2 | 3 | 3 | 2 | 5 | 6 | 5 | 5 | 12 | 8 |
| Interest | 3 | 2 | 4 | 5 | 4 | 2 | 6 | 5 | 5 | 7 | 8 |
| Depreciation | 6 | 5 | 8 | 9 | 10 | 10 | 10 | 10 | 9 | 10 | 13 |
| 33 | 44 | 60 | 41 | 55 | 53 | 44 | 37 | 42 | 70 | 79 | |
| Tax % | 25 | 30 | 27 | 24 | 27 | 26 | 26 | 26 | 24 | 25 | 25 |
| Net Profit | 25 | 31 | 44 | 31 | 40 | 40 | 32 | 27 | 32 | 52 | 59 |
| EPS | 29 | 36 | 52 | 37 | 47 | 46 | 38 | 32 | 37 | 61 | — |
| Dividend Payout % | 18 | 28 | 21 | 18 | 21 | 22 | 21 | 19 | 19 | 18 | — |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EPS | 29 | 36 | 52 | 37 | 47 | 46 | 38 | 32 | 37 | 61 | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 11%
- 5 Years:
- 7%
- 3 Years:
- 5%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 10%
- 5 Years:
- 5%
- 3 Years:
- 17%
STOCK PRICE CAGR
- 10 Years:
- 11%
- 5 Years:
- -2%
- 3 Years:
- 8%
- 1 Year:
- 8%
RETURN ON EQUITY
- 10 Years:
- 17%
- 5 Years:
- 12%
- 3 Years:
- 11%
- Last Year:
- 14%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| LIABILITIES | - | - | - | - | - | - | - | - | - | - |
| Equity Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| 114 | 138 | 171 | 195 | 229 | 260 | 284 | 304 | 331 | 377 | |
| 18 | 28 | 27 | 40 | 13 | 49 | 81 | 30 | 29 | 24 | |
| Trade Payables | 7 | 8 | 8 | 14 | 14 | 11 | 29 | 30 | 33 | 21 |
| 31 | 29 | 26 | 20 | 17 | 96 | 144 | 177 | 146 | 127 | |
| Total Liabilities | 178 | 210 | 240 | 277 | 282 | 424 | 546 | 550 | 546 | 557 |
| ASSETS | - | - | - | - | - | - | - | - | - | - |
| 61 | 67 | 101 | 97 | 87 | 84 | 108 | 103 | 105 | 288 | |
| Capital Work in Progress | 21 | 30 | 0 | 1 | 3 | 80 | 146 | 168 | 177 | 0 |
| 9 | 14 | 28 | 41 | 44 | 65 | 65 | 65 | 65 | 64 | |
| 33 | 39 | 48 | 60 | 57 | 71 | 79 | 69 | 59 | 60 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 86 | 81 | 92 | |
| Cash & Bank | 11 | 12 | 2 | 5 | 1 | 2 | 6 | 5 | 2 | 5 |
| 43 | 48 | 60 | 73 | 90 | 123 | 142 | 54 | 58 | 48 | |
| Total Assets | 178 | 210 | 240 | 277 | 282 | 424 | 546 | 550 | 546 | 557 |
| Total Debt | 39 | 43 | 38 | 48 | 16 | 122 | 164 | 134 | 104 | 74 |
| Net Working Capital | 41 | 47 | 60 | 65 | 105 | 92 | 80 | 107 | 89 | 98 |
| Contingent Liabilities | 1 | 1 | 28 | 106 | 103 | 106 | 115 | 117 | 120 | 133 |
| Book Value per Share | 143.52 | 171.72 | 210.93 | 238.72 | 279.28 | 315.54 | 343.70 | 367.59 | 398.60 | 452.78 |
| Face Value | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 | 32 | 36 | 26 | 41 | 16 | 33 | 43 | 64 | 51 | |
| Cash from Investing | -15 | -26 | -25 | -21 | -4 | -111 | -72 | -21 | -19 | -2 |
| Cash from Financing | -6 | -6 | -20 | -1 | -41 | 95 | 41 | -24 | -46 | -48 |
| 6 | -0 | -9 | 3 | -4 | 0 | 3 | -2 | -1 | 0 | |
| Free Cash Flow | 12 | 12 | 25 | 21 | 41 | -68 | -60 | 16 | 47 | 38 |
| OCF / Net Profit | 1.10 | 1.06 | 0.83 | 0.83 | 1.03 | 0.40 | 1.03 | 1.58 | 2.01 | 0.98 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 111 | 31 | -41 | -50 | -24 | -27 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| PER SHARE | ||||||||||
| EPS (₹) | 29.32 | 35.92 | 51.55 | 36.70 | 46.90 | 46.45 | 38.02 | 31.93 | 37.43 | 61.24 |
| Book Value (₹) | 143.52 | 171.72 | 210.93 | 238.72 | 279.28 | 315.54 | 343.70 | 367.59 | 398.60 | 452.78 |
| Dividend per Share (₹) | 5.30 | 10.00 | 11.00 | 6.60 | 10.00 | 10.00 | 8.00 | 6.00 | 7.00 | 11.00 |
| Cash EPS (₹) | 35.79 | 42.33 | 60.44 | 47.74 | 58.23 | 57.62 | 49.52 | 43.42 | 47.52 | 73.29 |
| PROFITABILITY | ||||||||||
| Operating Margin % | 33.29% | 38.06% | 41.39% | 32.85% | 35.32% | 29.48% | 23.53% | 16.42% | 17.77% | 23.18% |
| Net Margin % | 19.86% | 22.59% | 25.62% | 18.43% | 19.14% | 17.86% | 12.64% | 9.52% | 11.11% | 17.82% |
| ROE % | 22.43% | 22.79% | 26.94% | 16.33% | 18.11% | 15.62% | 11.53% | 8.98% | 9.77% | 14.39% |
| ROCE % | 24.16% | 26.28% | 31.15% | 19.74% | 23.28% | 17.31% | 11.91% | 9.26% | 10.59% | 17.02% |
| 14.79% | 15.71% | 19.46% | 12.07% | 14.27% | 11.19% | 6.67% | 4.96% | 5.81% | 9.44% | |
| EFFICIENCY | ||||||||||
| Debtor Days | 77 | 79 | 69 | 83 | 79 | 85 | 99 | 108 | 106 | 108 |
| Inventory Days | 97 | 97 | 93 | 117 | 103 | 105 | 107 | 94 | 81 | 74 |
| Payable Days | 81 | 120 | 99 | 135 | 94 | 72 | 91 | 107 | 121 | 118 |
| 93 | 56 | 63 | 66 | 87 | 118 | 115 | 95 | 66 | 64 | |
| FINANCIAL HEALTH | ||||||||||
| Debt to Equity (x) | 0.32x | 0.29x | 0.21x | 0.24x | 0.07x | 0.45x | 0.56x | 0.43x | 0.31x | 0.19x |
| Interest Coverage (x) | 11.31x | 19.88x | 17.87x | 9.19x | 14.88x | 22.58x | 7.76x | 8.21x | 8.78x | 10.72x |
| 2.20x | 2.10x | 2.53x | 2.12x | 4.03x | 2.22x | 1.58x | 2.09x | 1.92x | 2.06x | |
| GROWTH | ||||||||||
| Revenue Growth % | 22.19% | 9.33% | 27.01% | -1.03% | 23.05% | 5.22% | 15.80% | 12.27% | 0.46% | 1.98% |
| Operating Profit Growth % | 22.00% | 23.13% | 37.66% | -21.47% | 32.33% | -11.43% | -7.69% | -14.29% | 7.96% | 43.80% |
| Net Profit Growth % | 29.74% | 22.53% | 43.50% | -28.80% | 27.79% | -0.96% | -18.16% | -16.03% | 17.24% | 63.62% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -16.03% | 17.24% | 63.62% | |
| VALUATION | ||||||||||
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 43.52x | 33.50x | 20.62x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 3.78x | 3.15x | 2.79x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.43% | 0.56% | 0.87% |
| 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 25.39x | 20.98x | 14.28x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-08-27 - Hester Biosciences Limited has informed the Exchange about Credit Rating
2026-08-04 - Hester Biosciences Limited has informed the Exchange regarding Notice of Postal Ballot
2026-08-01 - Hester Biosciences Limited has informed the Exchange about Transcript
2026-07-31 - Hester Biosciences Limited has informed the Exchange about General Updates
2026-07-31 - Hester Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
2026-07-30 - Hester Biosciences Limited has informed the Exchange about Link of Recording
2026-07-30 - Hester Biosciences Limited has informed the Exchange regarding a press release dated July 30, 2026, titled "20260730 Q1 FY27 Press Release".
2026-07-30 - Hester Biosciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-25 - Hester Biosciences Limited has informed the Exchange about Schedule of meet
News
Recent coverage and analyst commentary for HESTERBIO
Loading news…
AI Stock Analyst
Hester Biosciences Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account

